Department of Internal Medicine, National Taiwan University Hospital , Taipei, Taiwan.
Faculty of Medicine and Surgery, University of Santo Tomas , Manila, Philippines.
Expert Rev Gastroenterol Hepatol. 2021 Mar;15(3):275-289. doi: 10.1080/17474124.2021.1840976. Epub 2021 Jan 19.
Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease of the colon, characterized by relapsing and remitting symptoms. Although traditionally viewed as a Western disease, the incidence and prevalence of UC is increasing in developing regions, including Asian countries.
A PubMed search identified articles describing epidemiology, disease burden, patient demographics, clinical characteristics, risk factors, and treatment of UC across Asia. We review the epidemiology and disease course of UC across Asia, including region-specific factors that may aid development of more cost-effective treatment approaches tailored to the needs of Asian populations.
The opinion of non-Pfizer-affiliated practicing gastroenterologists is that epidemiological data from the last four decades have shown 1.5-fold to almost 20-fold increases in the incidence and prevalence of UC in some Asian countries, although prevalence remains generally lower than in the West. As the prevalence of UC rises, so will overall healthcare costs. Disparities in healthcare systems and funding mean that different Asian countries face unique challenges in how best to use available resources, including selection from a growing number of emerging treatment options. More clinical trial and real-world data are required to help define treatment approaches that will most benefit Asian populations.
溃疡性结肠炎（UC）是一种特发性、慢性结肠炎症性疾病，其特征为反复发作和缓解。尽管溃疡性结肠炎传统上被视为一种西方疾病，但包括亚洲国家在内的发展中地区的发病率和患病率正在上升。
通过 PubMed 搜索，我们确定了描述亚洲各地溃疡性结肠炎的流行病学、疾病负担、患者人口统计学、临床特征、危险因素和治疗的文章。我们回顾了亚洲各地溃疡性结肠炎的流行病学和疾病进程，包括可能有助于制定更具成本效益的治疗方法的特定于区域的因素，这些方法可根据亚洲人群的需求进行定制。
非辉瑞关联的执业胃肠病学家的观点是，过去四十年的流行病学数据表明，一些亚洲国家的溃疡性结肠炎发病率和患病率增加了 1.5 至近 20 倍，尽管其患病率普遍仍低于西方国家。随着溃疡性结肠炎的患病率上升，整体医疗保健成本也将上升。医疗保健系统和资金的差异意味着不同的亚洲国家在如何最好地利用可用资源方面面临着独特的挑战，包括从越来越多的新兴治疗选择中进行选择。需要更多的临床试验和真实世界数据来帮助确定最有益于亚洲人群的治疗方法。
